Literature DB >> 9576194

Mutations of the granulocyte-colony stimulating factor receptor in patients with severe congenital neutropenia are not required for transformation to acute myeloid leukaemia and may be a bystander phenomenon.

T Bernard1, R E Gale, J P Evans, D C Linch.   

Abstract

Point mutations of the granulocyte-colony stimulating factor receptor (G-CSFR) resulting in an abnormally truncated receptor have been implicated in the pathogenesis of some cases of severe congenital neutropenia (SCN) and in the transformation of SCN to acute myeloid leukaemia (AML). We report here studies in 11 patients with SCN. No mutations were detected in the one patient who developed AML indicating that development of such mutations is not a prerequisite for transformation. Truncation mutations were detected in a minor percentage of transcripts from two other patients. In one patient the mutation has been constant at a low level (5-10% of total mRNA and 2/40 myeloid colonies) for 2 years. In the other patient the mutation was acquired, remained present at low levels for nearly 3 years and then spontaneously disappeared. Both patients had polyclonal haemopoiesis. We hypothesize that these mutations do not cause SCN, are randomly acquired with the mutant clone being expanded to detectable levels by high levels of exogenous or endogenous G-CSF, and may disappear by clonal succession. In a pre-leukaemic marrow the mutated subclone could achieve high levels, but this does not necessarily indicate a primary role of the mutant receptor in the leukaemogenic process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576194     DOI: 10.1046/j.1365-2141.1998.00652.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

Review 2.  Mechanisms of leukemic transformation in congenital neutropenia.

Authors:  Daniel C Link
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 3.  Neutrophil elastase in cyclic and severe congenital neutropenia.

Authors:  Marshall S Horwitz; Zhijun Duan; Brice Korkmaz; Hu-Hui Lee; Matthew E Mealiffe; Stephen J Salipante
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

4.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

Review 5.  Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

Authors:  Athanasia D Panopoulos; Stephanie S Watowich
Journal:  Cytokine       Date:  2008-04-08       Impact factor: 3.861

6.  Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS.

Authors:  Peter Vandenberghe; Karolien Beel
Journal:  Pediatr Rep       Date:  2011-06-22

7.  Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.

Authors:  Maksim Klimiankou; Murat Uenalan; Siarhei Kandabarau; Rainer Nustede; Ingeborg Steiert; Sabine Mellor-Heineke; Cornelia Zeidler; Julia Skokowa; Karl Welte
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

8.  Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene.

Authors:  M H Hermans; C Antonissen; A C Ward; A E Mayen; R E Ploemacher; I P Touw
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

Review 9.  Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy.

Authors:  Clifford Liongue; Alister Curtis Ward
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.